|
|
|
|
|
|
|
|
|
|
Reuters
"Novel biomarkers are the subject of intense controversy, with a bewildering variety of factions and perspectives seeking to elevate or dismiss any of a large number of proposed new measures. Now a new examination of the literature published online in JAMA Internal Medicine suggests that the evidence base used to evaluate novel biomarkers may be seriously compromised by selective reporting bias......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.